Key facts
- It has raised $580K across 2 recorded rounds; the latest was Seed Round ($275K) in Mar 2024.
- Pagari Life Science has filed 3 Form Ds with the SEC since 2023, most recently May 2025 ($56K sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Pagari Life Science
Funding rounds
2 roundsAbout Pagari Life Science
Developer of a biotechnology platform intended for the development and commercialization of a new generation of safe and effective therapeutics. The company offers anti-herpetic and advanced healing drugs that target viral deactivation, burn healing, pain control and wound treatment, enabling customers to treat and heal from a variety of conditions to extend their lifespan.
- Sector
- Healthcare
- HQ
- Bethalto, IL, United States
- Founded
- 2022
- Employees
- 4
- Website
- pagarilifescience.com/
- Ownership
- Privately Held (backing)
Pagari Life Science doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pagari Life Science shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pagari Life Science in its N-PORT filings yet. We sweep new filings monthly.